FDA Approves Genzyme's Renvela(TM) for Dialysi...(TM). There are also risks and uncertaint...)

Date:10/22/2007

TM). There are also risks and uncertainties described in reports filed by Genzyme with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation the information under the heading "Risk Factors" in the Management's Discussion and Analysis of Financial Condition and Results of Operations section of the Genzyme Quarterly Report on Form 10-Q for the quarter ending June 30, 2007. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this press release, and Genzyme undertakes no obligation to update or revise the statements.

Genzyme's press releases and other company information are available at http://www.genzyme.com and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States.

Genzyme(R) and Renagel(R) are registered trademarks and Renvela is a trademark of Genzyme Corporation. All rights reserved.

Media Contact: Investor Contact:

Erin Emlock Patrick Flanigan

(617) 768-6923 (617) 768-6563

'/>"/>

SOURCE Genzyme Corp. Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. UW-Madison approves new research institute
2. FDA approves GEs heart-imaging technology
3. Senate approves bill to expand stem cell funding
4. FDA approves advanced digital mammography system
5. Building commission approves Institutes for Discovery
6. UW Board of Regents approves $134 million medical research facility
7. FDA approves Bone Cares Hectorol for treatment of kidney disease
8. Sensitive detection of tumor cells in peripheral blood of carcinoma patients by a reverse transcription PCR method
9. Quantitation of GAD67 Gene Expression in Prefrontal Cortex of Schizophrenia Patients Using the iCycler iQ Detection System and Molecular Beacons, Rev A
10. What patients want: A story of choice, clinical trials & evidence-based medicine
11. Heart patients benefit from digital image network